11:52 AM EST - Trimel Pharmaceuticals Corporation : announced today that it has advised individual investigator clinical trial sites that the entire study is approaching full enrollment. As a consequence, the sites have been put on alert to closely monitor and report ongoing recruitment results in order to avoid added costs associated with over-enrollment. CompleoTRT™ is in development for the treatment of male hypogonadism, a condition that is estimated to affect up to 13 million men in the United States, with only 10% currently receiving treatment according to the latest epidemiological data. Trimel Pharmaceuticals Corporation
shares T.TRL are trading up $0.10 at $2.90.
